PEG-MGF at a glance
A fast read for beginners, with evidence strength, route context, safety depth, and community activity surfaced before the deeper sections.
Mechano Growth Factor (MGF) is an alternatively spliced variant of the IGF-1 gene that is produced locally in skeletal muscle in response to mechanical stress, damage, or exercise. The unique C-terminal E-domain peptide of MGF (the 24-amino acid sequence distinct from standard IGF-1) is the biologically active fragment responsible for activating muscle satellite cells - the quiescent progenitor cells that fuse with damaged muscle fibers to drive repair and growth.
The native MGF E-domain peptide has a very short half-life in circulation (minutes) due to rapid proteolytic degradation. PEG-MGF (pegylated MGF) attaches polyethylene glycol chains to the peptide, dramatically extending its half-life to approximately 72 hours and enabling systemic biodistribution - allowing it to reach muscle tissue throughout the body rather than only acting locally at the site of mechanical damage.
Preclinical research in rodents has demonstrated that PEG-MGF administration after muscle injury accelerates satellite cell proliferation, increases IGF-1R expression in damaged tissue, and significantly reduces recovery time. Unlike IGF-1 LR3, which activates the full IGF-1R signaling cascade, PEG-MGF's primary mechanism is upstream - it promotes satellite cell exit from quiescence and entry into the repair cycle.
No clinical trials have assessed PEG-MGF in humans. Community use is based entirely on extrapolation from animal models and theoretical pharmacology. It is typically used in research protocols following injury or intense training cycles, often stacked with IGF-1 LR3 for complementary anabolic activity.
Key Benefits
Saves this peptide to your Watchlist and helps you find new research, news, and questions later.